| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| paclitaxel | Injection, concentrated | 6 mg/mL | Current | Limited Availability | Manufacturing | 3/01/2025 |
| galantamine hydrobromide | Capsule, modified release | 10.252 mg | Anticipated | Available | Manufacturing | 3/01/2025 |
| galantamine hydrobromide | Capsule, modified release | 30.756 mg | Current | Limited Availability | Manufacturing | 3/01/2025 |
| galantamine hydrobromide | Capsule, modified release | 20.504 mg | Current | Unavailable | Manufacturing | 3/01/2025 |
| azithromycin dihydrate | Tablet, film coated | 524.05 mg | Current | Limited Availability | Manufacturing | 3/01/2025 |
| buprenorphine | Drug delivery system, transdermal | 5 mg | Current | Limited Availability | Manufacturing | 3/01/2025 |
| linezolid | Tablet, film coated | 600 mg | Anticipated | Available | Manufacturing | 3/01/2025 |
| azithromycin dihydrate | Tablet, film coated | 524 mg | Current | Limited Availability | Manufacturing | 3/01/2025 |
| fluorouracil | Injection, solution | 50 mg/mL | Current | Unavailable | Manufacturing | 3/01/2025 |
| cisplatin | Injection, concentrated | 1 mg/mL | Current | Unavailable | Unexpected increase in consumer demand | 3/01/2025 |
| potassium chloride | Injection, concentrated | 75 mg/mL | Current | Unavailable | Commercial Changes / Commercial viability | 3/01/2025 |
| mesalazine | Tablet, enteric coated | 1.6 g | Current | Limited Availability | Manufacturing | 3/01/2025 |
| Fremanezumab | Injection, solution | 225 mg | Resolved | Available | Unexpected increase in consumer demand | 3/01/2025 |
| sitagliptin fumarate | Tablet, film coated | 32.124 mg | Current | Unavailable | Manufacturing | 3/01/2025 |
| azithromycin dihydrate | Tablet, film coated | 524 mg | Current | Unavailable | Unexpected increase in consumer demand | 3/01/2025 |
| rifabutin | Capsule, hard | 150 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 3/01/2025 |
| aciclovir | Injection, solution | 25 mg/mL | Resolved | Available | Manufacturing | 3/01/2025 |
| azithromycin dihydrate | Tablet, film coated | 628.93 mg | Resolved | Available | Manufacturing | 3/01/2025 |
| fluticasone propionate | Inhalation, pressurised | 125 microgram/actuation | Current | Limited Availability | Unexpected increase in consumer demand | 3/01/2025 |
| estradiol~dydrogesterone | Tablet, film coated | 2 mg~10 mg | Anticipated | Available | Manufacturing | 3/01/2025 |
| pioglitazone hydrochloride | Tablet, uncoated | 33.06 mg | Anticipated | Available | Manufacturing | 3/01/2025 |
| morphine sulfate pentahydrate | Tablet, modified release | 10 mg | Current | Unavailable | Manufacturing | 2/01/2025 |
| morphine sulfate pentahydrate | Tablet, modified release | 30 mg | Current | Unavailable | Manufacturing | 2/01/2025 |
| morphine sulfate pentahydrate | Tablet, modified release | 60 mg | Current | Unavailable | Manufacturing | 2/01/2025 |
| morphine sulfate pentahydrate | Tablet, modified release | 100 mg | Current | Unavailable | Manufacturing | 2/01/2025 |
| venlafaxine | Capsule, modified release | 75 mg | Resolved | Available | Manufacturing | 2/01/2025 |
| venlafaxine | Capsule, modified release | 150 mg | Resolved | Available | Manufacturing | 2/01/2025 |
| metronidazole | Tablet, uncoated | 400 mg | Anticipated | Available | Manufacturing | 2/01/2025 |
| candesartan cilexetil | Tablet, uncoated | 4 mg | Current | Limited Availability | Manufacturing | 2/01/2025 |
| morphine hydrochloride trihydrate | Injection, solution | 10 mg/mL | Current | Limited Availability | Manufacturing | 2/01/2025 |
| pemetrexed disodium | Injection, powder for | 110.28 mg | Current | Unavailable | Manufacturing | 2/01/2025 |
| pemetrexed disodium | Injection, powder for | 551.4 mg | Current | Limited Availability | Manufacturing | 2/01/2025 |
| pemetrexed disodium | Injection, powder for | 1102.8 mg | Current | Unavailable | Manufacturing | 2/01/2025 |
| betahistine dihydrochloride | Tablet | 24 mg | Resolved | Available | Unexpected increase in consumer demand | 2/01/2025 |
| nebivolol hydrochloride | Tablet | 10.9 mg | Anticipated | Available | Manufacturing | 2/01/2025 |
| ropinirole hydrochloride | Tablet, film coated | .285 mg | Resolved | Available | Manufacturing | 2/01/2025 |
| risperidone | Tablet, film coated | .5 mg | Anticipated | Available | Manufacturing | 2/01/2025 |
| levothyroxine sodium | Tablet | .05 mg | Current | Unavailable | Manufacturing | 2/01/2025 |
| levothyroxine sodium | Tablet | .2 mg | Current | Limited Availability | Manufacturing | 2/01/2025 |
| levothyroxine sodium | Tablet | .1 mg | Current | Unavailable | Manufacturing | 2/01/2025 |
| fentanyl citrate | Injection, solution | 157 microgram | Current | Unavailable | Manufacturing | 2/01/2025 |
| levothyroxine sodium | Tablet | 50 microgram | Resolved | Available | Manufacturing | 2/01/2025 |
| melatonin | Capsule, hard | 5 mg | Resolved | Available | Unexpected increase in consumer demand | 2/01/2025 |
| melatonin | Oral Liquid, solution | 1 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 2/01/2025 |
| riboflavine sodium phosphate~folic acid~sodium pantothenate~Biotin~pyridoxine hydrochloride~cyanocobalamin~sodium ascorbate~nicotinamide~thiamine nitrate | Injection, powder for | 4.9 mg~.4 mg~16.5 mg~60 microgram~4.9 mg~5 microgram~113 mg~40 mg~3.1 mg | Resolved | Available | Manufacturing | 2/01/2025 |
| imipramine hydrochloride | Tablet, sugar coated | 25 mg | Current | Unavailable | Manufacturing | 2/01/2025 |
2025年1月6日